PT Kimia Farma Tbk (ISX:KAEF) Research & Development: Rp19,669 Mil (TTM As of Mar. 2026)


ISX:KAEF PT Kimia Farma Tbk ISX:KAEF
56 GF Score
Price Rp456.00
GF Value Rp581.98
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is PT Kimia Farma Tbk Research & Development?

PT Kimia Farma Tbk ISX:KAEF -2.15% 56 Research & Development is Rp19,669 Mil as of Mar. 2026. GuruFocus rates ISX:KAEF with a GF Score™ of 56/100 and a GF Value™ of Rp581.98 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PT Kimia Farma Tbk's Research & Development for the three months ended in Mar. 2026 was Rp3,198 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was Rp19,669 Mil.

PT Kimia Farma Tbk  (ISX:KAEF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PT Kimia Farma Tbk Research & Development Related Terms

PT Kimia Farma Tbk Research & Development Historical Data

* Premium members only.

The historical data trend for PT Kimia Farma Tbk's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PT Kimia Farma Tbk Research & Development Chart

PT Kimia Farma Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41,348.20 46,365.02 107,234.26 31,620.24 20,751.25

PT Kimia Farma Tbk Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,280.69 3,897.06 5,034.59 7,538.91 3,198.25
ISX:KAEF
56GF Score
PT Kimia Farma Tbk ISX:KAEF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PT Kimia Farma Tbk Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp19,669 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Rp19,669 Mil mean?
PT Kimia Farma Tbk (ISX:KAEF) has a Research & Development of Rp19,669 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PT Kimia Farma Tbk and its competitors.
Is PT Kimia Farma Tbk's Research & Development too high?
PT Kimia Farma Tbk's current Research & Development is Rp19,669 Mil. Overall, PT Kimia Farma Tbk has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Tbk's Research & Development compare to MCK and COR?
PT Kimia Farma Tbk's Research & Development of Rp19,669 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PT Kimia Farma Tbk and its competitors. PT Kimia Farma Tbk's current Research & Development is Rp19,669 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp581.98, compared to a current price of Rp456.00 — trading 21.6% below its estimated fair value. The current Research & Development is Rp19,669 Mil. PT Kimia Farma Tbk's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PT Kimia Farma Tbk (ISX:KAEF), the current Research & Development is Rp19,669 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PT Kimia Farma Tbk (ISX:KAEF) Overvalued in 2026?

Based on GuruFocus' analysis, PT Kimia Farma Tbk stock appears to be undervalued. The current stock price of Rp456.00 is trading 21.6% below its estimated GF Value™ of Rp581.98. GuruFocus considers PT Kimia Farma Tbk to be Modestly Undervalued.

Key valuation signals for ISX:KAEF:

  • Research & Development: Rp19,669 Mil
  • GF Value™: Rp581.98 vs. price of Rp456.00 (21.6% below fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PT Kimia Farma Tbk Business Description

Address Jalan Veteran No. 9 Gambir, Jakarta Pusat, Jakarta, IDN, 10110
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
56GF Score

Get the complete analysis for ISX:KAEF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Rp456.00
Price
Rp581.98
GF Value